Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the below web browsers.

Internet Explorer 9, Firefox, Chrome, or Safari.

CTAC News

ASO Sector's Disapproval with CDR's Drug Review Process

ASO Sector's Disapproval with CDR's Drug Review Process

february 18, 2014

Jennifer Peever's mother, Brenda, has been suffering with hepatitis C for 38 years.  At 59 years old she now suffers from Stage 4 cirrhosis of the liver.  Brenda could get help if the new drug, Sofosbuvir, were covered by the Ontario Health Insurance Plan (OHIP).  Unfortunately, Sofosbuvir will not be accessible to residents of Ontario until 2015 and the drug currently costs approximately $84,000 CAD! 2015 is too late for Brenda and far too late for many people suffering from this terrible disease across Canada! 

It is on behalf of Canadians like Brenda, that CTAC, along with 26 other HIV/AIDS NGOs and ASOs, healthcare providers and clinicians signed on to a letter expressing their disapproval with the Common Drug Review's (CDR) process of reviewing previously queued drug submissions.  The letter also expressed concern with the decision of the Canadian Agency for Drug Technology in Health's (CADTH) cancelled Canadian Drug Expert Committee meeting scheduled for this April. 

To read the full CTAC letter please click here.

To read CADTH's response to our letter, click here.

To read and sign onto Brenda's Change.org petition, click here.